Sign In
Buy IMNM
$22.76
-0.320 (-1.39%)
At Close: Jul 31, 2026
Immunome Announces Pricing of Public Offering of Common Stock
10:38pm, Tuesday, 13'th Feb 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today annou
Immunome Announces Proposed Public Offering of Common Stock
04:05pm, Tuesday, 13'th Feb 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today annou
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
09:36am, Wednesday, 07'th Feb 2024
Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.
Immunome to Present at the Stifel 2023 Healthcare Conference
08:00am, Friday, 10'th Nov 2023
SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Cla
7 Biotech Stocks to Get In Now Before Investors Catch On
02:50am, Monday, 23'rd Oct 2023
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
Immunome: The Morphimmune Merger And The Pipeline
03:11pm, Thursday, 28'th Sep 2023
IMNM is set to merge with Morphimmune, pending a shareholder vote on September 29. The current CEO of Morphimmune, Clay Siegall, would become the new CEO of IMNM. Siegall co-founded and led Seagen for
Immunome (IMNM) Surges on Merger Agreement With Morphimmune
11:27am, Friday, 30'th Jun 2023
Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.
Recent Price Trend in Immunome, Inc. (IMNM) is Your Friend, Here's Why
09:57am, Wednesday, 22'nd Mar 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunome, Inc. (IMNM) could be a great choice. It is one of the several stocks that passed through our "Recent
Immunome to Present at 13th Annual World ADC London Conference
08:45am, Thursday, 09'th Mar 2023
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient
Immunome: Clinical Data With A COVID Therapeutic And The AbbVie Collaboration
02:48am, Tuesday, 31'st Jan 2023
Topline data from Immunome's phase 1b trial of its COVID antibody drug, IMM-BCP-01, have led the company to look for a partner for further development. Even if IMNM can't find a partner for IMM-BCP-01
AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal
01:45pm, Friday, 06'th Jan 2023
AbbVie stock briefly broke out Friday after the company signed a $30 million deal with small biotech Immunome in antibody development. The post AbbVie Briefly Breaks Out After Tapping Immunome In $30
AbbVie and Immunome Partner to Find New Cancer Treatments
11:17am, Friday, 06'th Jan 2023
Immunome and AbbVie announced a worldwide collaboration and option agreement to discover up to 10 new antibody-target pairs for treating three specific types of tumors using Immunome's technology.
Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data
03:44pm, Thursday, 19'th May 2022
Immunome Inc (NASDAQ: IMNM) shares are trading higher after it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potently cleared the omicron variant (BA.1) when tested
Why Immunome Shares Are Rising
02:24pm, Thursday, 19'th May 2022
Immunome Inc (NASDAQ: IMNM) shares are trading higher by 19.44% at $3.39 after the company published data demonstrating its COVID-19 antibody cocktail IMM-BCP-01 cleared the omicron variant of SARS-Co
Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain
01:32pm, Monday, 14'th Mar 2022
Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.
